Walgreens Boots tops profit estimates as CEO's revamp efforts take hold

Reuters
2025/01/10
Walgreens Boots tops profit estimates as CEO's revamp efforts take hold

Jan 10 (Reuters) - Walgreens Boots Alliance WBA.O beat analysts' lowered expectations for first-quarter profit and maintained its annual forecast on Friday, as the healthcare company benefits from CEO Tim Wentworth's efforts to turn around its business.

The company, which operates the second-biggest pharmacy chain in the U.S. and Boots stores in the UK, has launched multiple rounds of store closures to its improve its profit and cash position.

"While our turnaround will take time, our early progress reinforces our belief in a sustainable, retail pharmacy-led operating model," Tim Wentworth said in a statement.

On a reported basis, the company posted a loss of 31 cents per share, versus 8 cents a year ago, due to costs related to its store closures and other one-time charges.

Excluding those items, Walgreens reported earnings of 51 cents per share for the quarter, compared with analysts' average estimate of 37 cents, according to data compiled by LSEG.

The company reiterated its 2025 adjusted profit forecast of $1.40 to $1.80 per share.

Walgreens' U.S. retail pharmacy unit posted sales of $30.9 billion for the quarter ended Nov. 30, above analysts' average estimate of $29.10 billion.

Investors have fled Walgreens as profits came under pressure from persistently low drug reimbursement rates and consumers avoiding high-priced grocery items. Shares of the Deerfield, Illinois-based company fell 64% in 2024.

In response, the company has unveiled a $1 billion cost-cutting program, as well as plans to close more than 1,200 stores over the next three years and remove multiple mid-level executives. It has also steadily sold its stake in drug distributor Cencora COR.N.

Media outlets, including the Wall Street Journal and Reuters, in December reported that Walgreens was looking to sell itself to private equity firm Sycamore Partners and had also reached out to other potential buyers. The company has declined to comment on the reports.

(Reporting by Manas Mishra and Sneha S K in Bengaluru; Editing by Sriraj Kalluvila)

((Sneha.SK@thomsonreuters.com;))

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10